Twelve gene therapies have been approved by the FDA to date to treat a variety of diseases, including the first ever gene edited therapeutic. The CMC package required to effectively demonstrate safety and efficacy of increasingly complex gene therapy products to regulators needs to keep pace.
Join your peers this July to:
- Understand how to transition your potency assay from early to late-stage
- Explore how NGS methods can better inform your genome titers
- Accurately measure partials in your samples
- Produce contaminant-free and high yield vector batches at scale
Secure your place here or get in touch with the team – info@hansonwade.com